U.S. Stem Cell, Inc. (USRM)

OTCMKTS: USRM · Delayed Price · USD
0.0000 (0.00%)
May 16, 2022 4:00 PM - Market closed
Market Cap4.12M
Revenue (ttm)200,749
Net Income (ttm)-3.29M
Shares Out571.63M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close0.0072
Day's Range0.0072 - 0.0075
52-Week Range0.0040 - 0.0300
Price Targetn/a
Earnings Daten/a

About USRM

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der...

IPO DateFeb 15, 2008
CEOMike Tomas
Stock ExchangeOTCMKTS
Ticker SymbolUSRM
Full Company Profile

Financial Performance

In 2020, U.S. Stem Cell's revenue was $277,087, a decrease of -90.98% compared to the previous year's $3.07 million. Losses were -$2.89 million, -24.64% less than in 2019.

Financial Statements


Mark Borman Appointed Chairman of the Board of USRM

SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions...

2 months ago - Accesswire